Short Interest in Rallybio Corporation (NASDAQ:RLYB) Declines By 72.5%

Rallybio Corporation (NASDAQ:RLYB) was the target of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 38,974 shares, a decrease of 72.5% from the January 29th total of 141,643 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 24,991 shares, the short-interest ratio is currently 1.6 days. Based on an average daily trading volume, of 24,991 shares, the short-interest ratio is currently 1.6 days. Currently, 0.8% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $40.00.

Rallybio Stock Performance

NASDAQ:RLYB opened at $6.80 on Friday. The company has a 50-day moving average of $5.34 and a 200-day moving average of $5.04. Rallybio has a 52 week low of $1.76 and a 52 week high of $6.81. The company has a market capitalization of $35.90 million, a price-to-earnings ratio of -2.66 and a beta of -1.05.

Institutional Investors Weigh In On Rallybio

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in shares of Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares in the last quarter. Citadel Advisors LLC grew its position in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the period. Geode Capital Management LLC raised its stake in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.